The life sciences sector is at a crossroads as the FDA updates quality management standards. AI is now expected, and the FDA’s January 2025 draft guidance outlines its evaluation and implementation. Successful adoption depends on three key questions.
Safe and Sane: Understanding the FDA’s Risk-Based Approach to AI
Related Posts
How Predictive Data Analytics Transforms Quality Assurance
What is Predictive Data Analytics? Types of Predictive Data Analytics How does Predictive Analytics Optimize QA and Testing?…
Enhancing Material Analysis: The Role of XRF and LIBS in Nondestructive Testing
XRF (X-Ray Fluorescence) and LIBS (Laser-Induced Breakdown Spectroscopy) are key nondestructive testing methods. XRF identifies elemental composition, while…
AI in Retail: The Playbook for Retail Transformation
The post AI in Retail: The Playbook for Retail Transformation first appeared on TestingXperts.
